Navigation Links
GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting

MEMPHIS, Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc., (NASDAQ: GTXI) announced today that data from the recent Phase II proof of concept clinical trial of Ostarine(TM) and from the ongoing Phase III clinical trial evaluating ACAPODENE(R) (toremifene citrate) 80 mg for the treatment of multiple side effects of androgen deprivation therapy (ADT) will be presented at the upcoming 2007 Annual Meeting of the American Society of Clinical Oncology being held June 1 - 5 at McCormick Place in Chicago.

William J. Evans, PhD, Professor of Geriatrics, Physiology, and Nutrition at the Donald W. Reynolds Institute on Aging at the University of Arkansas for Medical Sciences, will present the results of a Phase II proof of concept clinical trial evaluating the effects of Ostarine treatment on lean body mass and functional performance in 120 elderly males and postmenopausal females.

-- "Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients." Poster number: MM2. Abstract number: 9119.

-- Date and time: June 2, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

Matthew R. Smith, MD, PhD, Associate Professor of Medicine at Harvard Medical School and the Lead Principal Investigator of the Phase III ADT clinical trial, will present results of an interim lipid analysis conducted in the first 197 men to complete one year of the trial.

-- "Effect of toremifene in lowering total cholesterol, LDL, and triglycerides and raising HDL in prostate cancer patients on androgen deprivation therapy." Poster number: G6. Abstract number: 5124.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

S. Bruce Malkowicz, MD, Professor of Surgery at University of Pennsylvania School of Medicine, will present data detailing the prevalence at baseline of bone loss in patients participating
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:11/26/2014)... 2014 Investor-Edge has initiated coverage on ... Horizon Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. ... JNJ ), and Theravance Inc. (NASDAQ: THRX ... at: http://investor-edge.com/register . On Tuesday, November 25, ... Dow Jones Industrial Average edged 0.02% lower, to finish the ...
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Bank of ... , , , Date: , , , Wednesday, December 3, ... p.m. EST , , , , Location: , , , ... About BioScrip, Inc. BioScrip, Inc. is ...
(Date:11/26/2014)... Pa. , Nov. 26, 2014 ... to the development of innovative transdermal synthetic cannabinoid treatments, ... Piper Jaffray 26th Annual Healthcare Conference 2014. The conference ... New York Palace in New York ... will present at 4:50 pm on Tuesday, December 2. ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... Inc. (Nasdaq: STXS ) today announced that executive ... Conference on Tuesday, September 28, 2010 at 8:30 a.m. ET ... an overview of the Company,s business strategy and recent corporate ... invitation only. A live audio and slides webcast of Stereotaxis, ...
... BEDFORD, Mass., Sept. 23 Instrumentation Laboratory (IL), today announced ... on Wednesday, October 13, 2010 at the Grand Hyatt Nusa ... am to 12:00 pm, local time.  The forum will focus ... hemostasis.  All healthcare professionals, practicing in the Asia Pacific region ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference 2Stereotaxis to Present at the JMP Securities Healthcare Conference 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 2Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 3Instrumentation Laboratory to Host 2nd Asia Pacific Hemostasis Forum 4
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated litigation ... LLP reports. , Documents recently updated in ... records included in the state proceeding, all of ... bipolar disorder and other psychiatric conditions. Many of ...
(Date:11/27/2014)... WEDNESDAY, Nov. 26, 2014 (HealthDay News) -- Most babies ... a cold, the U.S. Food and Drug Administration says. ... be given to children younger than 2 because they ... agency warned. American adults average about three colds ... children get a cold, parents might want to give ...
(Date:11/27/2014)... (HealthDay News) -- Thanksgiving meals can pose a challenge ... an expert says. Many traditional Thanksgiving dishes -- ... -- are gluten-free, but "when it comes to pies, ... considered," Dr. Anca Safta, director of the Gluten and ... Center in North Carolina, said in a center news ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... Satisfaction Can Lead to Relationship, Quality-of-Life ... ... Leading sexual wellness experts,who attended a satellite symposium of the American ... agreed that,better intimacy can lead to better relationships and ultimately, better,overall ...
... threat, study finds, , , WEDNESDAY, Nov. 12 (HealthDay News) -- Whether ... you have a higher risk of dying than someone of normal ... to collect their weight around the middle -- apple-shaped -- face ... tends to settle in their hips and thighs -- pear-shaped. ...
... Medical Simulation Corporation (MSC),announces a new partnership with the ... and education services for USF Health hospital partners and ... education. The MSC SimSuite Education Center is located at ... , "MSC is excited to partner with USF Health ...
... cost-containment. , ... Alexandria, VA (Vocus) November 12, 2008 ... Chain Drug Stores (NACDS) Steven C. Anderson, IOM, CAE issued a ... Finance Committee Chairman Max Baucus (D-MT) today:, , , , ,“It ...
... that Hydrates and Soothes Young Throats Now Available,Across ... As cough and cold season,rapidly approaches, Integrated ... and nutrition products has launched its newest product,in ... product is a perfect choice for parents who ...
... industry award for 2008, WASHINGTON, Nov. ... of furniture for healthcare environments, today announced ... Nightingale Award at the,annual Healthcare Design 08 ... workspace solution, SYNC(TM)., (Photo: http://www.newscom.com/cgi-bin/prnh/20081112/AQW138 ...
Cached Medicine News:Health News:Experts at American Society for Reproductive Medicine (ASRM) Satellite Symposium Reach Consensus: Better Intimacy = Better Overall Well-Being 2Health News:Experts at American Society for Reproductive Medicine (ASRM) Satellite Symposium Reach Consensus: Better Intimacy = Better Overall Well-Being 3Health News:Excess Weight Ups Risk of Death, No Matter Where It Collects 2Health News:Medical Simulation Corp. announces partnership with University of South Florida 2Health News:As Chairman Baucus Outlines Vision for Healthcare Reform, NACDS Emphasizes Pharmacy's Essential Role in Any Successful Overhaul 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) in Canada 3Health News:Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution 2Health News:Nurture(R) by Steelcase Wins Second Consecutive Nightingale Award for SYNC(TM) Caregiver Workspace Solution 3
... molecular biology grade, standard melting temperature agarose that ... DNA, RNA, and PCR products = 1 kb. ... processing and blotting. Performance testing of NuSieve 3:1 ... to 1,000 bp, though this agarose is capable ...
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... gel strength, high electrophoretic mobility, and ... is the superior choice for CHEF ... easy to handle at concentrations as ... run times. Low background staining also ...
... general-purpose agarose, like the entire line of ... grade. This ensures that DNA recovered from ... compromising quality. Certified molecular biology agarose is ... molecular weight, resulting in a gel structure ...
Medicine Products: